4006-776-356 出国就医服务电话

免费获得国外相关药品,最快 1 个工作日回馈药物信息

出境医 / 临床实验 / Intrathecal Nalbuphine Versus Midazolam in Cesarean Section

Intrathecal Nalbuphine Versus Midazolam in Cesarean Section

Study Description
Brief Summary:

Adequate pain management is important to facilitate the functional recovery and enable the patients for rapid rehabilitation of normal activity .

Various adjuvants were being used with intrathecal bupivacain to prolong & improve postoperative pain relief in patients undergoing cesarean section .

The aim of this study was to compare intrathecal nalbuphine versus intrathecal midazolam in patient undergoing cesarean section. The investigators primary aims were to compare the characteristics of sensory and motor block, the effective analgesic time, and analgesic requirement. Secondary aims were to compare the side effects, sedation score and apgare score.


Condition or disease Intervention/treatment Phase
Cesarean Section Pain Drug: Bupivacaine Drug: Nalbuphine Drug: Midazolam Phase 1

Detailed Description:

Analgesia is the main point for each patient postoperatively. It is important to provide good analgesia with less hazardous (1). Cesarean section is a painful operation in need for adequate postoperative analgesia (1). Adequate pain management is important to facilitate the functional recovery and enable the patients for rapid rehabilitation of their normal activity (2).

Cesarean section was done under general anesthesia (GA) or regional anesthesia. The subarachnoid blockade is the preferred procedure (3). It avoids the depressant effect of GA on neonate and also the risk of aspiration, with better postoperative pain relief. However the most commonly local anesthetic used, hyperbaric bupivacaine has limited effect lasts for 1.5 - 2 hours (4). Its onset was slow with short duration of postoperative analgesia (3).

Adjuvant drugs added to bupivacaine intrathecally improve the duration and quality of the blockade and prolong the postoperative analgesia (5). Various adjuvants were being used such as alpha2 agonists, neostigmine, opiates, and ketamine etc, yet no drug was identified to specifically inhibit nociception without side effects (6).

Nalbuphine is a synthetic opioid with mixed agonist antagonist effect. It provides a significantly rapid onset of pain relief probably because of its lipophilic properties. It binds to both mu-and kappa receptors, binding of nalbuphine to mu receptors competitively displace other mu-agonists from these receptors without any agonist activity. Therefore decrease the side effects of mu agonist (nausea, vomiting, respiratory depression , urinary retention, pruritis and prolonged sedation) (7). While when binds to kappa receptors nalbuphine has agonist effect (analgesic effect) through the kappa receptors distributed in the brain and spinal cord(1). There were no documented studies of nalbuphine neurotoxicity (5, 8).

Benzodiazepines are used mainly for sedation, anoxiolysis and amnesia. Discovery of their receptors in spinal cord allow the use of midazolam intrathecally for analgesia. Several studies show that the addition of intrathecal midazolam potentiates the analgesic effect of intrathecal bupivacain without significant side effects, or neurotoxicity (9, 10).

There are several studies studied the effect of intrathecal nalbuphine and intrathecal midazolam but to The investigators knowledge no study compares between them.

The aim of this study was to compare intrathecal nalbuphine versus intrathecal midazolam in patient undergoing cesarean section. The investigators primary aims were to compare the characteristics of sensory and motor block, the effective analgesic time, and analgesic requirement. Secondary aims were to compare the side effects, sedation score and apgare score.

Study Design
Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Controlled comparative Double blind randomized study
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Health Services Research
Official Title: Nalbuphine Versus Midazolam as an Adjuvant to Intrathecal Bupivacaine for Postoperative Analgesia in Patients Undergoing Cesarean Section
Actual Study Start Date : April 10, 2019
Actual Primary Completion Date : August 30, 2019
Actual Study Completion Date : December 1, 2019
Arms and Interventions
Arm Intervention/treatment
Experimental: bupivacaine
12.5 mg hyperbaric bupivacaine + 0.5 ml 0.9% normal saline .
Drug: Bupivacaine
compare between nalbuphine versus midazolam as an adjuvant to intrathecal bupivacain to evaluate postoperative analgesia .

Active Comparator: nalbuphine
12.5 mg hyperbaric bupivacaine + 1 mg nalbuphine add in 0.5 ml 0.9% normal saline.
Drug: Nalbuphine
compare between nalbuphine versus midazolam as an adjuvant to intrathecal bupivacain to evaluate postoperative analgesia .

Active Comparator: midazolam
12.5 mg hyperbaric bupivacaine + 2.5 mg midazolam .
Drug: Midazolam
compare between nalbuphine versus midazolam as an adjuvant to intrathecal bupivacain to evaluate postoperative analgesia .

Outcome Measures
Primary Outcome Measures :
  1. Effective analgesic time [ Time Frame: up to six hours postoperative ]
    the time start from intrathecal injection to the first analgesic dose.

  2. Total postoperative analgesic dose . [ Time Frame: 24 hours ]
    the analgesic dose consumed

  3. Onset of sensory and motor block [ Time Frame: up tp five minutes after intrathecal injection ]
    the time of onset of sensory and motor block

  4. duration of sensory and motor block [ Time Frame: up to five hours postoperative ]
    the time of duration of sensory and motor block


Secondary Outcome Measures :
  1. Sedation score [ Time Frame: one hour during surgery ]

    score of sedation:

    1= awake and alert 2 = sedated ,respond to verbal stimules 3= sedated respond to a mild physical status 4=sedated respond to a moderate or strong physical stimuls 5= not arousable 5 is the higher value


  2. Apgar score [ Time Frame: 1-5 minutes after delivery ]
    score for baby

  3. number of participants with hypotension , bradycardia ,vomiting , nausea , shivering number of participants with hypotension , bradycardia ,vomiting , nausea , shivering [ Time Frame: up to 24 hours postoperative ]
    incidence of hypotension , bradycardia ,vomiting , nausea , shivering


Eligibility Criteria
Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria: -

  • Female gender .
  • Age : 18 - 40 years old .
  • Physical status : ASA II .
  • Elective cesarean section

Exclusion Criteria:

  • - Patient refusal .
  • History of hypertension or cardiac diseases .
  • Psychiatric disorders .
  • Coagulopathy .
  • Allergy to study drugs .
  • Contraindication to spinal anesthesia .
  • Failure of spinal anesthesia .
Contacts and Locations

Locations
Layout table for location information
Egypt
Olfat Abd Elmoniem Ibrahem Amin
Zagazig, Eygpt/zagazig, Egypt, 002055
Sponsors and Collaborators
Zagazig University
Investigators
Layout table for investigator information
Principal Investigator: Olfat A I Amin, MD Zagazig University
Tracking Information
First Submitted Date  ICMJE April 7, 2019
First Posted Date  ICMJE April 17, 2019
Last Update Posted Date December 24, 2019
Actual Study Start Date  ICMJE April 10, 2019
Actual Primary Completion Date August 30, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 14, 2019)
  • Effective analgesic time [ Time Frame: up to six hours postoperative ]
    the time start from intrathecal injection to the first analgesic dose.
  • Total postoperative analgesic dose . [ Time Frame: 24 hours ]
    the analgesic dose consumed
  • Onset of sensory and motor block [ Time Frame: up tp five minutes after intrathecal injection ]
    the time of onset of sensory and motor block
  • duration of sensory and motor block [ Time Frame: up to five hours postoperative ]
    the time of duration of sensory and motor block
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: November 26, 2019)
  • Sedation score [ Time Frame: one hour during surgery ]
    score of sedation: 1= awake and alert 2 = sedated ,respond to verbal stimules 3= sedated respond to a mild physical status 4=sedated respond to a moderate or strong physical stimuls 5= not arousable 5 is the higher value
  • Apgar score [ Time Frame: 1-5 minutes after delivery ]
    score for baby
  • number of participants with hypotension , bradycardia ,vomiting , nausea , shivering number of participants with hypotension , bradycardia ,vomiting , nausea , shivering [ Time Frame: up to 24 hours postoperative ]
    incidence of hypotension , bradycardia ,vomiting , nausea , shivering
Original Secondary Outcome Measures  ICMJE
 (submitted: April 14, 2019)
  • Sedation score [ Time Frame: one hour during surgery ]
    score of sedation: 1= awake and alert 2 = sedated ,respond to verbal stimules 3= sedated respond to a mild physical status 4=sedated respond to a moderate or strong physical stimuls 5= not arousable 5 is the higher value
  • Apgar score [ Time Frame: 1-5 minutes after delivery ]
    score for baby
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Intrathecal Nalbuphine Versus Midazolam in Cesarean Section
Official Title  ICMJE Nalbuphine Versus Midazolam as an Adjuvant to Intrathecal Bupivacaine for Postoperative Analgesia in Patients Undergoing Cesarean Section
Brief Summary

Adequate pain management is important to facilitate the functional recovery and enable the patients for rapid rehabilitation of normal activity .

Various adjuvants were being used with intrathecal bupivacain to prolong & improve postoperative pain relief in patients undergoing cesarean section .

The aim of this study was to compare intrathecal nalbuphine versus intrathecal midazolam in patient undergoing cesarean section. The investigators primary aims were to compare the characteristics of sensory and motor block, the effective analgesic time, and analgesic requirement. Secondary aims were to compare the side effects, sedation score and apgare score.

Detailed Description

Analgesia is the main point for each patient postoperatively. It is important to provide good analgesia with less hazardous (1). Cesarean section is a painful operation in need for adequate postoperative analgesia (1). Adequate pain management is important to facilitate the functional recovery and enable the patients for rapid rehabilitation of their normal activity (2).

Cesarean section was done under general anesthesia (GA) or regional anesthesia. The subarachnoid blockade is the preferred procedure (3). It avoids the depressant effect of GA on neonate and also the risk of aspiration, with better postoperative pain relief. However the most commonly local anesthetic used, hyperbaric bupivacaine has limited effect lasts for 1.5 - 2 hours (4). Its onset was slow with short duration of postoperative analgesia (3).

Adjuvant drugs added to bupivacaine intrathecally improve the duration and quality of the blockade and prolong the postoperative analgesia (5). Various adjuvants were being used such as alpha2 agonists, neostigmine, opiates, and ketamine etc, yet no drug was identified to specifically inhibit nociception without side effects (6).

Nalbuphine is a synthetic opioid with mixed agonist antagonist effect. It provides a significantly rapid onset of pain relief probably because of its lipophilic properties. It binds to both mu-and kappa receptors, binding of nalbuphine to mu receptors competitively displace other mu-agonists from these receptors without any agonist activity. Therefore decrease the side effects of mu agonist (nausea, vomiting, respiratory depression , urinary retention, pruritis and prolonged sedation) (7). While when binds to kappa receptors nalbuphine has agonist effect (analgesic effect) through the kappa receptors distributed in the brain and spinal cord(1). There were no documented studies of nalbuphine neurotoxicity (5, 8).

Benzodiazepines are used mainly for sedation, anoxiolysis and amnesia. Discovery of their receptors in spinal cord allow the use of midazolam intrathecally for analgesia. Several studies show that the addition of intrathecal midazolam potentiates the analgesic effect of intrathecal bupivacain without significant side effects, or neurotoxicity (9, 10).

There are several studies studied the effect of intrathecal nalbuphine and intrathecal midazolam but to The investigators knowledge no study compares between them.

The aim of this study was to compare intrathecal nalbuphine versus intrathecal midazolam in patient undergoing cesarean section. The investigators primary aims were to compare the characteristics of sensory and motor block, the effective analgesic time, and analgesic requirement. Secondary aims were to compare the side effects, sedation score and apgare score.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Controlled comparative Double blind randomized study
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Health Services Research
Condition  ICMJE Cesarean Section Pain
Intervention  ICMJE
  • Drug: Bupivacaine
    compare between nalbuphine versus midazolam as an adjuvant to intrathecal bupivacain to evaluate postoperative analgesia .
  • Drug: Nalbuphine
    compare between nalbuphine versus midazolam as an adjuvant to intrathecal bupivacain to evaluate postoperative analgesia .
  • Drug: Midazolam
    compare between nalbuphine versus midazolam as an adjuvant to intrathecal bupivacain to evaluate postoperative analgesia .
Study Arms  ICMJE
  • Experimental: bupivacaine
    12.5 mg hyperbaric bupivacaine + 0.5 ml 0.9% normal saline .
    Intervention: Drug: Bupivacaine
  • Active Comparator: nalbuphine
    12.5 mg hyperbaric bupivacaine + 1 mg nalbuphine add in 0.5 ml 0.9% normal saline.
    Intervention: Drug: Nalbuphine
  • Active Comparator: midazolam
    12.5 mg hyperbaric bupivacaine + 2.5 mg midazolam .
    Intervention: Drug: Midazolam
Publications * Amin OAI, Ibrahem MA, Salem DAE. Nalbuphine versus Midazolam as an Adjuvant to Intrathecal Bupivacaine for Postoperative Analgesia in Patients Undergoing Cesarean Section. J Pain Res. 2020 Jun 11;13:1369-1376. doi: 10.2147/JPR.S242545. eCollection 2020.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 14, 2019)
90
Original Actual Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE December 1, 2019
Actual Primary Completion Date August 30, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria: -

  • Female gender .
  • Age : 18 - 40 years old .
  • Physical status : ASA II .
  • Elective cesarean section

Exclusion Criteria:

  • - Patient refusal .
  • History of hypertension or cardiac diseases .
  • Psychiatric disorders .
  • Coagulopathy .
  • Allergy to study drugs .
  • Contraindication to spinal anesthesia .
  • Failure of spinal anesthesia .
Sex/Gender  ICMJE
Sexes Eligible for Study: Female
Ages  ICMJE 18 Years to 40 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Egypt
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03918187
Other Study ID Numbers  ICMJE 5305
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Responsible Party olfat abd elmoniem ibrahem, Zagazig University
Study Sponsor  ICMJE Zagazig University
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Olfat A I Amin, MD Zagazig University
PRS Account Zagazig University
Verification Date December 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP